TransCode Therapeutics, Inc. (RNAZ)

TransCode Therapeutics Inc. is a biotechnology company betting that small pieces of RNA, when delivered to the right place inside cancer cells, can kill metastatic tumors. The bet hinges on two things working: first, finding RNA sequences that switch off the cellular machinery driving metastasis, and second, delivering those sequences to tumor cells without them getting lost on the way. TransCode calls the delivery problem “the lethal challenge” of RNA oncology. It has spent years building nanoparticles designed to solve it, and in 2024 it moved its lead candidate into human trials.

The Metastasis Problem

Most people who die of cancer do not die from their original tumor. They die when that tumor spreads — metastasizes — to distant organs. A surgeon can often remove the primary tumor. Chemotherapy or radiation can shrink it. But once cancer cells have scattered into the lungs, the liver, the bones, the brain, the standard playbook fails. The tumor is everywhere, and killing all of it without poisoning the patient becomes nearly impossible.

Metastasis is a different disease from the primary tumor. It requires cancer cells to acquire new abilities — to break away, survive in the bloodstream, invade distant tissue, and then root themselves and grow in an alien environment. These abilities are controlled partly by proteins, and protein-coding genes can be targeted by drugs. But some of the control comes from regulatory RNA — in particular, microRNAs — which are much smaller molecules and much harder to target with conventional drugs.

TransCode’s insight is that one specific microRNA, called microRNA-10b or miR-10b, is a master switch for metastatic spread across many tumor types. If you could shut off miR-10b, you could slow or halt the metastatic machinery in breast, ovarian, pancreatic, colon cancers, and glioblastomas. But the trick is delivering an RNA-based drug that shuts it off to the tumor cells themselves, rather than to healthy cells or into the bloodstream where it gets destroyed before it reaches the cancer.

The Delivery Solution: The TTX Platform

Here is where TransCode’s nanoparticle technology matters. The company developed a platform it calls TTX — a modular nanoparticle built from iron oxide. Iron oxide is biocompatible (the body tolerates it), and it can be loaded with cargo: the therapeutic RNA. The nanoparticle is designed to accumulate in tumors, where it releases its payload.

Most RNA therapeutics get stuck. They work well for the liver — a big, filtering organ that naturally traps small molecules — but they fail in other tissues. The liver is the easiest tumor to hit; solid tumors outside the liver are much harder. TransCode’s nanoparticles address this. They are functionalized to target tumor cells specifically, to avoid clearance by the immune system, and to release their RNA cargo once inside the tumor. This is difficult engineering, and TransCode has built a body of preclinical and animal data supporting the approach.

The iron oxide platform is modular. The same nanoparticle can carry different RNA payloads. TransCode can test TTX combined with miR-10b inhibitors, or other therapeutic RNAs, or even combinations that the company has not yet discovered. That optionality is valuable. If the miR-10b strategy fails, the platform can be aimed at other targets.

From Bench to Patient: TTX-MC138

In late 2024 and into 2025, TransCode moved its lead candidate, TTX-MC138, into a Phase I/II clinical trial. This is human testing — the first time the nanoparticle and RNA combination would be given to cancer patients. Phase I trials are small and designed to establish safety and dosage. Phase II trials are larger and designed to begin measuring whether the drug actually shrinks tumors.

TTX-MC138 is an anti-miR-10b therapy — it is the miR-10b-inhibiting RNA loaded into TransCode’s nanoparticles. The trial is recruiting patients with metastatic cancers, those same cancer types in which miR-10b is known to play a role. Success would mean finding that the drug is tolerable and shows signals of efficacy — tumors shrinking, patients’ clinical status improving, or both.

Clinical trials in oncology are slow and uncertain. Patients with metastatic disease are often quite sick. Safety concerns, manufacturing problems, or a lack of efficacy can derail a program. TransCode’s path to commercialization will take years and requires the trial to show not only safety but clear benefit over existing options. For a small biotech company with limited cash, that path is expensive.

The Science and the Validation

What gives TransCode credibility is the scientific foundation. The company has partnerships with major research institutions including Massachusetts General Hospital and MD Anderson Cancer Center, two of the top cancer research centers in the world. These partnerships validate the science and provide collaborative research that strengthens the pipeline.

The microRNA and nanoparticle approaches are not TransCode’s invention — both fields are decades old. What the company is doing is combining known science with engineering to create something testable. That is how most drug development works: combining pieces that exist, refining them, and seeing whether the result has biological activity in humans.

Capital, Cash Burn, and the Timeline

TransCode, like all clinical-stage biotechs, does not generate revenue. It burns cash on research, clinical trials, manufacturing, and personnel. The company must raise capital constantly to fund its operations. As of 2025, TransCode secured flexible financing agreements that the company said would extend its cash runway into late 2027 or early 2028.

This means TransCode has roughly two years to demonstrate that TTX-MC138 is worth pursuing further. If the Phase I/II data looks promising, investors and partners will be eager to fund Phase III trials and commercialization. If the data is disappointing, the company may have to deprioritize the program, pivot to other candidates, or wind down.

How to Research TransCode

The SEC filings (CIK 0001829635) contain the company’s financial position, capital needs, and risk factors. The investor relations page posts clinical trial updates and milestones. The most useful information comes from clinical trial publications and presentations at major oncology conferences, where the company discloses efficacy data as it accumulates. For biotech, the science is the business. The nanoparticle delivery technology works in animals; the open question is whether it works in humans and whether the miR-10b target matters enough to justify the cost and side effects of treatment.